about
Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies.Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients.A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization.Population pharmacokinetics of polymyxin B in acutely ill adult patients.Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.Measuring the impact of varying denominator definitions on standardized antibiotic consumption rates: implications for antimicrobial stewardship programmesPolymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients1821. Understanding the Components and Calculation of the SAAR, Illustrative Data1419. 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury1406. Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling with Bayesian Estimation in Children in the Pediatric Intensive Care Unit1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational StudiesA Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of CefepimeA Review of the Clinical Pharmacokinetics of Polymyxin BEvaluation of Dose Fractionated Polymyxin B on Acute Kidney Injury: A Translational In Vivo Rat ModelDevelopment of Population and Bayesian Models for Applied Use in Patients Receiving CefepimeUnderstanding the Components, Calculation, and Impact of Monthly and Seasonal Variation of the Standardized Antimicrobial Utilization Ratio (SAAR)Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICUVancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysisThe Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis PatientsTwenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat modelImplementation of an Extended-Infusion Piperacillin-Tazobactam Dosing Protocol: Unexpected Findings when Monitoring Safety and Compliance with Smart Pump TechnologyEvaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat ModelComparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury
P50
Q38627075-6354CF7D-942A-4FC5-A35E-0BF393B15C55Q40162234-9F4DFDC0-3D02-4DE6-9E1C-69AB80942305Q40218376-18A5EF4F-F0DA-420E-B70D-984347AC599DQ47195590-FC291C31-CDAB-4A9C-A10A-38FD3B955D6FQ47195600-E9C6A5F5-8E4D-43F6-9E5D-36C494E54532Q57779595-4826D288-7A92-4E4F-B79E-C6842B4D484EQ57779600-ECBCBCC6-2716-4F31-B62B-BD973D32F2C7Q59327773-50D0F6DC-C6E3-4C42-B5BC-09E6EE1248D7Q59333811-9064B230-D6CE-4FA2-9C38-961CEB5143B5Q59333863-4B7F8C11-AAF9-4D2D-80D9-C7B4E2F35F01Q59334522-A1542270-71B5-4A56-AF55-AAAD9C7F169BQ59334621-B3CEC0CD-0D75-452A-8EA3-17753EFA4AB3Q61806330-C21C237F-A519-4C4F-AE37-555BDA842C8BQ64059428-274A94FF-C703-4AC1-946F-FF0DDAD53E35Q89765993-D5D9EF4E-34F3-4C37-8924-88BE0ECE21A8Q90096916-72A8BCBD-D2A3-4258-B010-7779F3F5A63DQ90852891-778D9E6B-33B9-4C06-950A-C788B1D266E9Q90925070-B9C4B000-E8E3-4D1D-9178-07B194872023Q91329463-5D89602F-D779-4EE1-8481-3F339E6E24D6Q91688590-F738A056-C1F2-450F-AB84-C374AFD22A3AQ91838866-49ACF761-45CF-4CD8-AC1D-B5F5031D7862Q91966474-B7ED5973-CFB1-49BC-B2B9-DE535889D160Q92091303-264891EA-81DD-4EE0-A460-4170C528C76CQ93110539-D512B886-24CE-43F5-9D91-304A1981144A
P50
description
Amerikaans onderzoeker
@nl
docteur et chercheur en pharmacie
@fr
hulumtues
@sq
investigador estauxunidense
@ast
researcher
@en
հետազոտող
@hy
name
Sean N. Avedissian
@ast
Sean N. Avedissian
@ca
Sean N. Avedissian
@en
Sean N. Avedissian
@es
Sean N. Avedissian
@fr
Sean N. Avedissian
@nl
Sean N. Avedissian
@sl
type
label
Sean N. Avedissian
@ast
Sean N. Avedissian
@ca
Sean N. Avedissian
@en
Sean N. Avedissian
@es
Sean N. Avedissian
@fr
Sean N. Avedissian
@nl
Sean N. Avedissian
@sl
prefLabel
Sean N. Avedissian
@ast
Sean N. Avedissian
@ca
Sean N. Avedissian
@en
Sean N. Avedissian
@es
Sean N. Avedissian
@fr
Sean N. Avedissian
@nl
Sean N. Avedissian
@sl
P106
P1412
P21
P2650
P31
P496
0000-0002-0935-6455